Immunomodulation and disease tolerance to Staphylococcus aureus

Pathogens

Volumn 4, Issue 4, 2015, Pages 793-815

  Li, Zhigang ^a   Peres, Adam G ^a   Damian, Andreea C ^a   Madrenas, Joaquín ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Disease tolerance; Immunomodulation; Interleukin 10; Microbiome; Staphylococcus aureus

Indexed keywords

DECTIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA;

ENDOCARDITIS; IMMUNE EVASION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INNATE IMMUNITY; MICROBIOME; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; PNEUMONIA; REVIEW; SEPSIS; STAPHYLOCOCCUS INFECTION; TOXIC SHOCK SYNDROME;

EID: 85014582516     PISSN: None     EISSN: 20760817     Source Type: Journal    
DOI: 10.3390/pathogens4040793     Document Type: Review

References (141)

1. Lowy, F.D. Staphylococcus aureus infections. N. Engl. J. Med. 1998, 339, 520–532.
2. Brown, A.F.; Leech, J.M.; Rogers, T.R.; McLoughlin, R.M. Staphylococcus aureus colonization: Modulation of host immune response and impact on human vaccine design. Front. Immunol. 2014, 4, 507.
3. Chen, L.F. The changing epidemiology of methicillin-resistant Staphylococcus aureus: 50 years of a superbug. Am. J. Infect. Control 2013, 41, 448–451.
4. Miller, L.S.; Cho, J.S. Immunity against Staphylococcus aureus cutaneous infections. Nat. Rev. Immunol. 2011, 11, 505–518.
5. Dantes, R.; Mu, Y.; Belflower, R.; Aragon, D.; Dumyati, G.; Harrison, L.H.; Lessa, F.C.; Lynfield, R.; Nadle, J.; Petit, S. et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections, united states, 2011. JAMA Intern. Med. 2013, 173, 1970–1978.
6. Stentzel, S.; Sundaramoorthy, N.; Michalik, S.; Nordengrun, M.; Schulz, S.; Kolata, J.; Kloppot, P.; Engelmann, S.; Steil, L.; Hecker, M. et al. Specific serum igg at diagnosis of Staphylococcus aureus bloodstream invasion is correlated with disease progression. J. Proteom. 2015, 128, 1–7.
7. Wertheim, H.F. Melles, D.C. Vos, M.C. van Leeuwen, W. van Belkum, A. Verbrugh, H.A. Nouwen, J.L. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect. Dis. 2005, 5, 751–762.
8. Bar-Gal, G.K. Blum, S.E. Hadas, L. Ehricht, R. Monecke, S. Leitner, G. Host-specificity of Staphylococcus aureus causing intramammary infections in dairy animals assessed by genotyping and virulence genes. Vet. Microbiol. 2015, 176, 143–154.
9. Pishchany, G. McCoy, A.L. Torres, V.J. Krause, J.C. Crowe, J.E., Jr. Fabry, M.E. Skaar, E.P. Specificity for human hemoglobin enhances Staphylococcus aureus infection. Cell Host Microbe 2010, 8, 544–550.
10. Peres, A.G. Madrenas, J. The broad landscape of immune interactions with Staphylococcus aureus: From commensalism to lethal infections. Burns 2013, 39, 380–388.
11. Wertheim, H.F. Vos, M.C. Ott, A. van Belkum, A. Voss, A. Kluytmans, J.A. van Keulen, P.H. Vandenbroucke-Grauls, C.M. Meester, M.H. Verbrugh, H.A. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004, 364, 703–705.
12. Netsvyetayeva, I. Fraczek, M. Piskorska, K. Golas, M. Sikora, M. Swoboda-Kopec, E. Mlynarczyk, A. Marusza, W. Palmieri, B. Iannitti, T. Staphylococcus aureus nasal carriage in ukraine: Antibacterial resistance and virulence factor encoding genes. BMC Infect. Dis. 2014, 14, 128.
13. Kawai, T. Akira, S. The role of pattern-recognition receptors in innate immunity: Update on toll-like receptors. Nat. Immunol. 2010, 11, 373–384.
14. Figdor, C.G. van Kooyk, Y. Adema, G.J. C-type lectin receptors on dendritic cells and langerhans cells. Nat. Rev. Immunol. 2002, 2, 77–84.
15. Frodermann, V. Chau, T.A. Sayedyahossein, S. Toth, J.M. Heinrichs, D.E. Madrenas, J. A modulatory interleukin-10 response to staphylococcal peptidoglycan prevents Th1/Th17 adaptive immunity to Staphylococcus aureus. J Infect Dis 2011, 204, 253–262.
16. Skabytska, Y. Wolbing, F. Gunther, C. Koberle, M. Kaesler, S. Chen, K.M. Guenova, E. Demircioglu, D. Kempf, W.E. Volz, T. et al. Cutaneous innate immune sensing of toll-like receptor 2–6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells. Immunity 2014, 41, 762–775.
17. Takeuchi, O. Hoshino, K. Akira, S. Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J. Immunol. 2000, 165, 5392–5396.
18. Von Bernuth, H. Picard, C. Jin, Z. Pankla, R. Xiao, H. Ku, C.L. Chrabieh, M. Mustapha, I.B. Ghandil, P. Camcioglu, Y. et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008, 321, 691–696.
19. Alsina, L. Israelsson, E. Altman, M.C. Dang, K.K. Ghandil, P. Israel, L. von Bernuth, H. Baldwin, N. Qin, H. Jin, Z. et al. A narrow repertoire of transcriptional modules responsive to pyogenic bacteria is impaired in patients carrying loss-of-function mutations in MyD88 or IRAK4. Nat. Immunol. 2014, 15, 1134–1142.
20. Tomlinson, G. Chimalapati, S. Pollard, T. Lapp, T. Cohen, J. Camberlein, E. Stafford, S. Periselneris, J. Aldridge, C. Vollmer, W. et al. TLR-mediated inflammatory responses to streptococcus pneumoniae are highly dependent on surface expression of bacterial lipoproteins. J. Immunol. 2014, 193, 3736–3745.
21. Takeuchi, O. Akira, S. Pattern recognition receptors and inflammation. Cell 2010, 140, 805–820.
22. Peres, A.G. Stegen, C. Li, J. Xu, A.Q. Levast, B. Surette, M.G. Cousineau, B. Desrosiers, M. Madrenas, J. Uncoupling of pro- and anti-inflammatory properties of Staphylococcus aureus. Infect. Immun.2015, 83, 1587–1597.
23. Greenlee-Wacker, M.C. Rigby, K.M. Kobayashi, S.D. Porter, A.R. DeLeo, F.R. Nauseef, W.M. Phagocytosis of Staphylococcus aureus by human neutrophils prevents macrophage efferocytosis and induces programmed necrosis. J. Immunol. 2014, 192, 4709–4717.
24. McLoughlin, R.M. Lee, J.C. Kasper, D.L. Tzianabos, A.O. Ifn-gamma regulated chemokine production determines the outcome of Staphylococcus aureus infection. J. Immunol. 2008, 181, 1323–1332.
25. Montgomery, C.P. Daniels, M. Zhao, F. Alegre, M.L. Chong, A.S. Daum, R.S. Protective immunity against recurrent Staphylococcus aureus skin infection requires antibody and interleukin-17a. Infect. Immun. 2014, 82, 2125–2134.
26. Milner, J.D. Brenchley, J.M. Laurence, A. Freeman, A.F. Hill, B.J. Elias, K.M. Kanno, Y. Spalding, C. Elloumi, H.Z. Paulson, M.L. et al.Impaired T(h)17 cell differentiation in subjects with autosomal dominant hyper-ige syndrome. Nature 2008, 452, 773–776.
27. Soltesz, B. Toth, B. Sarkadi, A.K. Erdos, M. Marodi, L. The evolving view of IL-17-mediated immunity in defense against mucocutaneous candidiasis in humans. Int. Rev. Immunol. 2015, 34, 348–363.
28. Okada, S. Markle, J.G. Deenick, E.K. Mele, F. Averbuch, D. Lagos, M. Alzahrani, M. Al-Muhsen, S. Halwani, R. Ma, C.S. et al. Immunodeficiencies. Impairment of immunity to candida and mycobacterium in humans with bi-allelic rorc mutations. Science 2015, 349, 606–613.
29. Grumann, D. Scharf, S.S. Holtfreter, S. Kohler, C. Steil, L. Engelmann, S. Hecker, M. Volker, U. Broker, B.M. Immune cell activation by enterotoxin gene cluster (egc)-encoded and non-egc superantigens from Staphylococcus aureus. J. Immunol. 2008, 181, 5054–5061.
30. Dauwalder, O. Thomas, D. Ferry, T. Debard, A.L. Badiou, C. Vandenesch, F. Etienne, J. Lina, G. Monneret, G. Comparative inflammatory properties of staphylococcal superantigenic enterotoxins sea and seg: Implications for septic shock. J. Leukoc Biol.2006, 80, 753–758.
31. Kolata, J.B. Kuhbandner, I. Link, C. Normann, N. Vu, C.H. Steil, L. Weidenmaier, C. Broker, B.M. The fall of a dogma? Unexpected high T-cell memory response to Staphylococcus aureus in humans. J. Infect. Dis.2015, 212, 830–838.
32. Schlievert, P.M. The dream of staphylococcal vaccination. J. Exp. Med.2014, 211, 2326.
33. Lee, C.C. Avalos, A.M. Ploegh, H.L. Accessory molecules for toll-like receptors and their function. Nat. Rev. Immunol. 2012, 12, 168–179.
34. Hasan, U. Chaffois, C. Gaillard, C. Saulnier, V. Merck, E. Tancredi, S. Guiet, C. Briere, F. Vlach, J. Lebecque, S. et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J. Immunol. 2005, 174, 2942–2950.
35. Oosting, M. Cheng, S.C. Bolscher, J.M. Vestering-Stenger, R. Plantinga, T.S. Verschueren, I.C. Arts, P. Garritsen, A. van Eenennaam, H. Sturm, P. et al. Human TLR10 is an anti-inflammatory pattern-recognition receptor. Proc. Natl. Acad. Sci. USA 2014, 111, E4478–E4484.
36. Mogensen, T.H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 2009, 22, 240–273.
37. Becker, K. Friedrich, A.W. Lubritz, G. Weilert, M. Peters, G. von Eiff, C. Prevalence of genes encoding pyrogenic toxin superantigens and exfoliative toxins among strains of Staphylococcus aureus isolated from blood and nasal specimens. J. Clin. Microbiol. 2003, 41, 1434–1439.
38. Mempel, M. Lina, G. Hojka, M. Schnopp, C. Seidl, H.P. Schafer, T. Ring, J. Vandenesch, F. Abeck, D. High prevalence of superantigens associated with the egc locus in Staphylococcus aureus isolates from patients with atopic eczema. Eur. J. Clin. Microbiol. Infect. Dis. 2003, 22, 306–309.
39. Nashev, D. Toshkova, K. Salasia, S.I. Hassan, A.A. Lammler, C. Zschock, M. Distribution of virulence genes of Staphylococcus aureus isolated from stable nasal carriers. FEMS Microbiol. Lett. 2004, 233, 45–52.
40. Davis, J.P. Chesney, P.J. Wand, P.J. LaVenture, M. Toxic-shock syndrome: Epidemiologic features, recurrence, risk factors, and prevention. N. Engl. J. Med.1980, 303, 1429–1435.
41. Reduced incidence of menstrual toxic-shock syndrome--United States, 1980–1990. MMWR Morb. Mortal Wkly Rep. 1990, 39, 421–423.
42. Chau, T.A. McCully, M.L. Brintnell, W. An, G. Kasper, K.J. Vines, E.D. Kubes, P. Haeryfar, S.M. McCormick, J.K. Cairns, E. et al. Toll-like receptor 2 ligands on the staphylococcal cell wall downregulate superantigen-induced T cell activation and prevent toxic shock syndrome. Nat. Med. 2009, 15, 641–648.
43. Lai, Y. di Nardo, A. Nakatsuji, T. Leichtle, A. Yang, Y. Cogen, A.L. Wu, Z.R. Hooper, L.V. Schmidt, R.R. von Aulock, S. et al. Commensal bacteria regulate toll-like receptor 3-dependent inflammation after skin injury. Nat. Med. 2009, 15, 1377–1382.
44. Tkaczyk, C. Hamilton, M.M. Datta, V. Yang, X.P. Hilliard, J.J. Stephens, G.L. Sadowska, A. Hua, L. O’Day, T. Suzich, J. et al. Staphylococcus aureus alpha toxin suppresses effective innate and adaptive immune responses in a murine dermonecrosis model. PLoS ONE 2013, 8, e75103.
45. Hawrylowicz, C.M. O’Garra, A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat. Rev. Immunol. 2005, 5, 271–283.
46. Moore, K.W. de Waal Malefyt, R. Coffman, R.L. O’Garra, A. Interleukin-10 and the interleukin- 10 receptor. Annu. Rev. Immunol. 2001, 19, 683–765.
47. Sendide, K. Deghmane, A.E. Pechkovsky, D. Av-Gay, Y. Talal, A. Hmama, Z. Mycobacterium bovis bcg attenuates surface expression of mature class II molecules through IL-10-dependent inhibition of cathepsin s. J. Immunol. 2005, 175, 5324–5332.
48. Willems, F. Marchant, A. Delville, J.P. Gerard, C. Delvaux, A. Velu, T. de Boer, M. Goldman, M. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur. J. Immunol. 1994, 24, 1007–1009.
49. Buelens, C. Willems, F. Delvaux, A. Pierard, G. Delville, J.P. Velu, T. Goldman, M. Interleukin-10 differentially regulates B7–1 (CD80) and B7–2 (CD86) expression on human peripheral blood dendritic cells. Eur. J. Immunol. 1995, 25, 2668–2672.
50. Thurlow, L.R. Hanke, M.L. Fritz, T. Angle, A. Aldrich, A. Williams, S.H. Engebretsen, I.L. Bayles, K.W. Horswill, A.R. Kielian, T. Staphylococcus aureus biofilms prevent macrophage phagocytosis and attenuate inflammation in vivo. J. Immunol. 2011, 186, 6585–6596.
51. Hanke, M.L. Heim, C.E. Angle, A. Sanderson, S.D. Kielian, T. Targeting macrophage activation for the prevention and treatment of Staphylococcus aureus biofilm infections. J. Immunol. 2013, 190, 2159–2168.
52. Krysko, O. Holtappels, G. Zhang, N. Kubica, M. Deswarte, K. Derycke, L. Claeys, S. Hammad, H. Brusselle, G.G. Vandenabeele, P. et al. Alternatively activated macrophages and impaired phagocytosis of S. aureus in chronic rhinosinusitis. Allergy 2011, 66, 396–403.
53. Xu, F. Kang, Y. Zhang, H. Piao, Z. Yin, H. Diao, R. Xia, J. Shi, L. Akt1-mediated regulation of macrophage polarization in a murine model of Staphylococcus aureus pulmonary infection. J. Infect Dis.2013, 208, 528–538.
54. Kabelitz, D. Expression and function of toll-like receptors in T lymphocytes. Curr. Opin. Immunol. 2007, 19, 39–45.
55. Zielinski, C.E. Mele, F. Aschenbrenner, D. Jarrossay, D. Ronchi, F. Gattorno, M. Monticelli, S. Lanzavecchia, A. Sallusto, F. Pathogen-induced human Th17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature 2012, 484, 514–518.
56. Rabe, H. Nordstrom, I. Andersson, K. Lundell, A.C. Rudin, A. Staphylococcus aureus convert neonatal conventional cd4(+) T cells into Foxp3(+) CD25(+) CD127(low) T cells via the PD-1/PDlL axis. Immunology 2014, 141, 467–481.
57. Rose, W.E. Eickhoff, J.C. Shukla, S.K. Pantrangi, M. Rooijakkers, S. Cosgrove, S.E. Nizet, V. Sakoulas, G. Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with Staphylococcus aureus bacteremia. J. Infect. Dis. 2012, 206, 1604–1611.
58. Tebartz, C. Horst, S.A. Sparwasser, T. Huehn, J. Beineke, A. Peters, G. Medina, E. A major role for myeloid-derived suppressor cells and a minor role for regulatory T cells in immunosuppression during Staphylococcus aureus infection. J. Immunol. 2015, 194, 1100–1111.
59. Wang, J. Roderiquez, G. Norcross, M.A. Control of adaptive immune responses by Staphylococcus aureus through IL-10, PD-L1, and TLR2. Sci. Rep. 2012, 2, 606.
60. Lee, L.Y. Miyamoto, Y.J. McIntyre, B.W. Hook, M. McCrea, K.W. McDevitt, D. Brown, E.L. The Staphylococcus aureus map protein is an immunomodulator that interferes with T cell-mediated responses. J. Clin. Invest. 2002, 110, 1461–1471.
61. Santos-Sierra, S. Deshmukh, S.D. Kalnitski, J. Kuenzi, P. Wymann, M.P. Golenbock, D.T. Henneke, P. Mal connects TLR2 to PI3kinase activation and phagocyte polarization. EMBO J. 2009, 28, 2018–2027.
62. Cao, S. Zhang, X. Edwards, J.P. Mosser, D.M. Nf-kappab1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages. J. Biol. Chem. 2006, 281, 26041–26050.
63. Brenner, S. Prosch, S. Schenke-Layland, K. Riese, U. Gausmann, U. Platzer, C. Camp-induced interleukin-10 promoter activation depends on ccaat/enhancer-binding protein expression and monocytic differentiation. J. Biol. Chem. 2003, 278, 5597–5604.
64. Liu, Y.W. Tseng, H.P. Chen, L.C. Chen, B.K. Chang, W.C. Functional cooperation of simian virus 40 promoter factor 1 and ccaat/enhancer-binding protein beta and delta in lipopolysaccharideinduced gene activation of IL-10 in mouse macrophages. J. Immunol. 2003, 171, 821–828.
65. Ananieva, O. Darragh, J. Johansen, C. Carr, J.M. McIlrath, J. Park, J.M. Wingate, A. Monk, C.E. Toth, R. Santos, S.G. et al. The kinases msk1 and msk2 act as negative regulators of toll-like receptor signaling. Nat. Immunol. 2008, 9, 1028–1036.
66. Ziegler-Heitbrock, L. Lotzerich, M. Schaefer, A. Werner, T. Frankenberger, M. Benkhart, E. Ifn-alpha induces the human IL-10 gene by recruiting both IFN regulatory factor 1 and stat3. J. Immunol. 2003, 171, 285–290.
67. Brightbill, H.D. Plevy, S.E. Modlin, R.L. Smale, S.T. A prominent role for sp1 during lipopolysaccharide-mediated induction of the IL-10 promoter in macrophages. J. Immunol. 2000, 164, 1940–1951.
68. Tone, M. Powell, M.J. Tone, Y. Thompson, S.A. Waldmann, H. IL-10 gene expression is controlled by the transcription factors sp1 and sp3. J. Immunol. 2000, 165, 286–291.
69. Ruimy, R. Angebault, C. Djossou, F. Dupont, C. Epelboin, L. Jarraud, S. Lefevre, L.A. Bes, M. Lixandru, B.E. Bertine, M. et al. Are host genetics the predominant determinant of persistent nasal Staphylococcus aureus carriage in humans? J. Infect. Dis. 2010, 202, 924–934.
70. Alva-Murillo, N. Tellez-Perez, A.D. Medina-Estrada, I. Alvarez-Aguilar, C. Ochoa-Zarzosa, A. Lopez-Meza, J.E. Modulation of the inflammatory response of bovine mammary epithelial cells by cholecalciferol (vitamin D) during Staphylococcus aureus internalization. Microb. Pathog. 2014, 77, 24–30.
71. Reed, S.G. TGF-beta in infections and infectious diseases. Microbes Infect.1999, 1, 1313–1325.
72. Neill, D.R. Coward, W.R. Gritzfeld, J.F. Richards, L. Garcia-Garcia, F.J. Dotor, J. Gordon, S.B. Kadioglu, A. Density and duration of pneumococcal carriage is maintained by transforming growth factor beta1 and T regulatory cells. Am. J. Respir. Crit. Care Med. 2014, 189, 1250–1259.
73. Andreotti, C.S. Pereyra, E.A. Baravalle, C. Renna, M.S. Ortega, H.H. Calvinho, L.F. Dallard, B.E. Staphylococcus aureus chronic intramammary infection modifies protein expression of transforming growth factor beta (TGF-beta) subfamily components during active involution. Res. Vet. Sci. 2014, 96, 5–14.
74. Soares, M.P. Gozzelino, R. Weis, S. Tissue damage control in disease tolerance. Trends Immunol.2014, 35, 483–494.
75. Medzhitov, R. Schneider, D.S. Soares, M.P. Disease tolerance as a defense strategy. Science 2012, 335, 936–941.
76. Raberg, L. Sim, D. Read, A.F. Disentangling genetic variation for resistance and tolerance to infectious diseases in animals. Science 2007, 318, 812–814.
77. Larsen, R. Gozzelino, R. Jeney, V. Tokaji, L. Bozza, F.A. Japiassu, A.M. Bonaparte, D. Cavalcante, M.M. Chora, A. Ferreira, A. et al. A central role for free heme in the pathogenesis of severe sepsis. Sci. Transl. Med. 2010, 2, 51ra71.
78. Figueiredo, N. Chora, A. Raquel, H. Pejanovic, N. Pereira, P. Hartleben, B. Neves-Costa, A. Moita, C. Pedroso, D. Pinto, A. et al. Anthracyclines induce DNA damage response-mediated protection against severe sepsis. Immunity 2013, 39, 874–884.
79. Maurer, K. Reyes-Robles, T. Alonzo, F., 3rd; Durbin, J. Torres, V.J. Cadwell, K. Autophagy mediates tolerance to Staphylococcus aureus alpha-toxin. Cell Host Microbe 2015, 17, 429–440.
80. Chen, J.Y. Hour, T.C. Yang, S.F. Chien, C.Y. Chen, H.R. Tsai, K.L. Ko, J.Y. Wang, L.F. Autophagy is deficient in nasal polyps: Implications for the pathogenesis of the disease. Int. Forum. Allergy Rhinol. 2015, 5, 119–123.
81. Hermann, I. Rath, S. Ziesemer, S. Volksdorf, T. Dress, R.J. Gutjahr, M. Muller, C. Beule, A.G. Hildebrandt, J.P. Staphylococcus aureus hemolysin a disrupts cell-matrix adhesions in human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 2015, 52, 14–24.
82. Malik, Z. Roscioli, E. Murphy, J. Ou, J. Bassiouni, A. Wormald, P.J. Vreugde, S. Staphylococcus aureus impairs the airway epithelial barrier in vitro. Int. Forum. Allergy Rhinol. 2015, 5, 551–556.
83. Burian, M. Wolz, C. Goerke, C. Regulatory adaptation of Staphylococcus aureus during nasal colonization of humans. PLoS ONE 2010, 5, e10040.
84. Jenkins, A. Diep, B.A. Mai, T.T. Vo, N.H. Warrener, P. Suzich, J. Stover, C.K. Sellman, B.R. Differential expression and roles of Staphylococcus aureus virulence determinants during colonization and disease. mBio 2015, 6, e02272–02214.
85. Todd, J. Fishaut, M. Kapral, F. Welch, T. Toxic-shock syndrome associated with phage-group-i staphylococci. Lancet 1978, 2, 1116–1118.
86. McCormick, J.K. Yarwood, J.M. Schlievert, P.M. Toxic shock syndrome and bacterial superantigens: An update. Annu. Rev. Microbiol. 2001, 55, 77–104.
87. Llewelyn, M. Cohen, J. Superantigens: Microbial agents that corrupt immunity. Lancet Infect. Dis. 2002, 2, 156–162.
88. Murray, R.J. Recognition and management of Staphylococcus aureus toxin-mediated disease. Intern. Med. J. 2005, 35 (Suppl. 2), S106–S119.
89. Annane, D. Clair, B. Salomon, J. Managing toxic shock syndrome with antibiotics. Expert Opin. Pharmacother. 2004, 5, 1701–1710.
90. Kuhn, R. Lohler, J. Rennick, D. Rajewsky, K. Muller, W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75, 263–274.
91. Glocker, E.O. Kotlarz, D. Boztug, K. Gertz, E.M. Schaffer, A.A. Noyan, F. Perro, M. Diestelhorst, J. Allroth, A. Murugan, D. et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med.2009, 361, 2033–2045.
92. Lu, J. Philpott, D.J. Saunders, P.R. Perdue, M.H. Yang, P.C. McKay, D.M. Epithelial ion transport and barrier abnormalities evoked by superantigen-activated immune cells are inhibited by interleukin-10 but not interleukin-4. J. Pharmacol. Exp. Ther. 1998, 287, 128–136.
93. Kasper, K.J. Zeppa, J.J. Wakabayashi, A.T. Xu, S.X. Mazzuca, D.M. Welch, I. Baroja, M.L. Kotb, M. Cairns, E. Cleary, P.P. et al. Bacterial superantigens promote acute nasopharyngeal infection by Streptococcus pyogenes in a human MHC class II-dependent manner. PLoS Pathog. 2014, 10, e1004155.
94. Muller, B. de Groot, E.J. Kortekaas, I.J. Fokkens, W.J. van Drunen, C.M. Nasal epithelial cells express IL-10 at levels that negatively correlate with clinical symptoms in patients with house dust mite allergy. Allergy 2007, 62, 1014–1022.
95. Muller, B. de Groot, E.J. Kortekaas, I.J. Fokkens, W.J. van Drunen, C.M. Nasal endothelial interleukin-10 expression is negatively correlated with nasal symptoms after allergen provocation. Allergy 2009, 64, 738–745.
96. Bessede, A. Gargaro, M. Pallotta, M.T. Matino, D. Servillo, G. Brunacci, C. Bicciato, S. Mazza, E.M. Macchiarulo, A. Vacca, C. et al. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature 2014, 511, 184–190.
97. Okumura, C.Y. Nizet, V. Subterfuge and sabotage: Evasion of host innate defenses by invasive gram-positive bacterial pathogens. Annu. Rev. Microbiol. 2014, 68, 439–458.
98. Thammavongsa, V. Kim, H.K. Missiakas, D. Schneewind, O. Staphylococcal manipulation of host immune responses. Nat. Rev. Microbiol. 2015, 13, 529–543.
99. Rooijakkers, S.H. Ruyken, M. Roos, A. Daha, M.R. Presanis, J.S. Sim, R.B. van Wamel, W.J. van Kessel, K.P. van Strijp, J.A. Immune evasion by a staphylococcal complement inhibitor that acts on c3 convertases. Nat. Immunol. 2005, 6, 920–927.
100. Hair, P.S. Echague, C.G. Sholl, A.M. Watkins, J.A. Geoghegan, J.A. Foster, T.J. Cunnion, K.M. Clumping factor a interaction with complement factor i increases c3b cleavage on the bacterial surface of Staphylococcus aureus and decreases complement-mediated phagocytosis. Infect. Immun. 2010, 78, 1717–1727.
101. Jongerius, I. Kohl, J. Pandey, M.K. Ruyken, M. van Kessel, K.P. van Strijp, J.A. Rooijakkers, S.H. Staphylococcal complement evasion by various convertase-blocking molecules. J. Exp. Med.2007, 204, 2461–2471.
102. Jusko, M. Potempa, J. Kantyka, T. Bielecka, E. Miller, H.K. Kalinska, M. Dubin, G. Garred, P. Shaw, L.N. Blom, A.M. Staphylococcal proteases aid in evasion of the human complement system. J. Innate Immun. 2014, 6, 31–46.
103. Laarman, A.J. Ruyken, M. Malone, C.L. van Strijp, J.A. Horswill, A.R. Rooijakkers, S.H. Staphylococcus aureus metalloprotease aureolysin cleaves complement C3 to mediate immune evasion. J. Immunol. 2011, 186, 6445–6453.
104. De Haas, C.J. Veldkamp, K.E. Peschel, A. Weerkamp, F. van Wamel, W.J. Heezius, E.C. Poppelier, M.J. van Kessel, K.P. van Strijp, J.A. Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J. Exp. Med.2004, 199, 687–695.
105. Thakker, M. Park, J.S. Carey, V. Lee, J.C. Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Infect. Immun.1998, 66, 5183–5189.
106. Watts, A. Ke, D. Wang, Q. Pillay, A. Nicholson-Weller, A. Lee, J.C. Staphylococcus aureus strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence. Infect. Immun. 2005, 73, 3502–3511.
107. Ip, W.K. Sokolovska, A. Charriere, G.M. Boyer, L. Dejardin, S. Cappillino, M.P. Yantosca, L.M. Takahashi, K. Moore, K.J. Lacy-Hulbert, A. et al. Phagocytosis and phagosome acidification are required for pathogen processing and MyD88-dependent responses to Staphylococcus aureus. J. Immunol. 2010, 184, 7071–7081.
108. Shi, L. Takahashi, K. Dundee, J. Shahroor-Karni, S. Thiel, S. Jensenius, J.C. Gad, F. Hamblin, M.R. Sastry, K.N. Ezekowitz, R.A. Mannose-binding lectin-deficient mice are susceptible to infection with Staphylococcus aureus. J. Exp. Med. 2004, 199, 1379–1390.
109. Falugi, F. Kim, H.K. Missiakas, D.M. Schneewind, O. Role of protein A in the evasion of host adaptive immune responses by Staphylococcus aureus. mBio 2013, 4, doi:10.1128/mBio.00575-13.
110. Mandell, G.L. Catalase, superoxide dismutase, and virulence of Staphylococcus aureus. In vitro and in vivo studies with emphasis on staphylococcal--leukocyte interaction. J. Clin. Invest.1975, 55, 561–566.
111. Karavolos, M.H. Horsburgh, M.J. Ingham, E. Foster, S.J. Role and regulation of the superoxide dismutases of Staphylococcus aureus. Microbiology 2003, 149, 2749–2758.
112. Bera, A. Biswas, R. Herbert, S. Kulauzovic, E. Weidenmaier, C. Peschel, A. Gotz, F. Influence of wall teichoic acid on lysozyme resistance in Staphylococcus aureus. J. Bacteriol. 2007, 189, 280–283.
113. Shimada, T. Park, B.G. Wolf, A.J. Brikos, C. Goodridge, H.S. Becker, C.A. Reyes, C.N. Miao, E.A. Aderem, A. Gotz, F. et al. Staphylococcus aureus evades lysozyme-based peptidoglycan digestion that links phagocytosis, inflammasome activation, and IL-1beta secretion. Cell Host Microbe 2010, 7, 38–49.
114. O’Leary, S. O’Sullivan, M.P. Keane, J. IL-10 blocks phagosome maturation in mycobacterium tuberculosis-infected human macrophages. Am. J. Respir. Cell Mol. Biol. 2011, 45, 172–180.
115. Bobadilla, K. Sada, E. Jaime, M.E. Gonzalez, Y. Ramachandra, L. Rojas, R.E. Michalak, C. Pedraza-Sanchez, S. Gonzalez-Noriega, A. Torres, M. Human phagosome processing of mycobacterium tuberculosis antigens is modulated by interferon-gamma and interleukin-10. Immunology 2013, 138, 34–46.
116. Thammavongsa, V. Kern, J.W. Missiakas, D.M. Schneewind, O. Staphylococcus aureus synthesizes adenosine to escape host immune responses. J. Exp. Med.2009, 206, 2417–2427.
117. Thammavongsa, V. Missiakas, D.M. Schneewind, O. Staphylococcus aureus degrades neutrophil extracellular traps to promote immune cell death. Science 2013, 342, 863–866.
118. Panther, E. Corinti, S. Idzko, M. Herouy, Y. Napp, M. la Sala, A. Girolomoni, G. Norgauer, J. Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the t-cell stimulatory capacity of human dendritic cells. Blood 2003, 101, 3985–3990.
119. Panther, E. Idzko, M. Herouy, Y. Rheinen, H. Gebicke-Haerter, P.J. Mrowietz, U. Dichmann, S. Norgauer, J. Expression and function of adenosine receptors in human dendritic cells. FASEB J. 2001, 15, 1963–1970.
120. Mascanfroni, I.D. Takenaka, M.C. Yeste, A. Patel, B. Wu, Y. Kenison, J.E. Siddiqui, S. Basso, A.S. Otterbein, L.E. Pardoll, D.M. et al. Metabolic control of type 1 regulatory T cell differentiation by ahr and hif1-alpha. Nat. Med. 2015, 21, 638–646.
121. Koppelman, B. Neefjes, J.J. de Vries, J.E. de Waal Malefyt, R. Interleukin-10 down-regulates mhc class ii alphabeta peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling. Immunity 1997, 7, 861–871.
122. Ding, L. Linsley, P.S. Huang, L.Y. Germain, R.N. Shevach, E.M. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J. Immunol. 1993, 151, 1224–1234.
123. De Waal Malefyt, R. Abrams, J. Bennett, B. Figdor, C.G. de Vries, J.E. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J. Exp. Med.1991, 174, 1209–1220.
124. Shibata, Y. Foster, L.A. Kurimoto, M. Okamura, H. Nakamura, R.M. Kawajiri, K. Justice, J.P. van Scott, M.R. Myrvik, Q.N. Metzger, W.J. Immunoregulatory roles of IL-10 in innate immunity: IL-10 inhibits macrophage production of ifn-gamma-inducing factors but enhances nk cell production of ifn-gamma. J. Immunol. 1998, 161, 4283–4288.
125. Nagamatsu, K. Kuwae, A. Konaka, T. Nagai, S. Yoshida, S. Eguchi, M. Watanabe, M. Mimuro, H. Koyasu, S. Abe, A. Bordetella evades the host immune system by inducing IL-10 through a type iii effector, bopn. J. Exp. Med. 2009, 206, 3073–3088.
126. Bourgeois-Nicolaos, N. Lucet, J.C. Daubie, C. Benchaba, F. Rajguru, M. Ruimy, R. Andremont, A. Armand-Lefevre, L. Maternal vaginal colonisation by Staphylococcus aureus and newborn acquisition at delivery. Paediatr. Perinat Epidemiol. 2010, 24, 488–491.
127. Shinefield, H. Black, S. Fattom, A. Horwith, G. Rasgon, S. Ordonez, J. Yeoh, H. Law, D. Robbins, J.B. Schneerson, R. et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 2002, 346, 491–496.
128. DeJonge, M. Burchfield, D. Bloom, B. Duenas, M. Walker, W. Polak, M. Jung, E. Millard, D. Schelonka, R. Eyal, F. et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J. Pediatr. 2007, 151, 260–265.
129. Pauli, N.T. Kim, H.K. Falugi, F. Huang, M. Dulac, J. Henry Dunand, C. Zheng, N.Y. Kaur, K. Andrews, S.F. Huang, Y. et al. Staphylococcus aureus infection induces protein A-mediated immune evasion in humans. J. Exp. Med.2014, 211, 2331–2339.
130. Bean, A.G. Freiberg, R.A. Andrade, S. Menon, S. Zlotnik, A. Interleukin 10 protects mice against staphylococcal enterotoxin b-induced lethal shock. Infect. Immun. 1993, 61, 4937–4939.
131. Krakauer, T. Inhibition of toxic shock syndrome toxin-1-induced cytokine production and T cell activation by interleukin-10, interleukin-4, and dexamethasone. J. Infect. Dis. 1995, 172, 988–992.
132. Marlow, G.J. van Gent, D. Ferguson, L.R. Why interleukin-10 supplementation does not work in Crohn's disease patients. World J. Gastroenterol. 2013, 19, 3931–3941.
133. Martini, M. Ciraolo, E. Gulluni, F. Hirsch, E. Targeting PI3K in cancer: Any good news? Front. Oncol. 2013, 3, 108.
134. Rafii, S. Roda, D. Geuna, E. Jimenez, B. Rihawi, K. Capelan, M. Yap, T.A. Molife, L.R. Kaye, S.B. de Bono, J.S. et al. Higher risk of infections with PI3K-Akt-mTOR pathway inhibitors in patients with advanced solid tumors on phase i clinical trials. Clin. Cancer Res. 2015, 21, 1869–1876.
135. Kaymakcalan, M.D. Je, Y. Sonpavde, G. Galsky, M. Nguyen, P.L. Heng, D.Y. Richards, C.J. Choueiri, T.K. Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors. Br. J. Cancer 2013, 108, 2478–2484.
136. Cohen, P. Targeting protein kinases for the development of anti-inflammatory drugs. Curr. Opin. Cell Biol. 2009, 21, 317–324.
137. Goldstein, D.M. Kuglstatter, A. Lou, Y. Soth, M.J. Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J. Med. Chem.2010, 53, 2345–2353.
138. Genovese, M.C. Cohen, S.B. Wofsy, D. Weinblatt, M.E. Firestein, G.S. Brahn, E. Strand, V. Baker, D.G. Tong, S.E. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral scio-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J. Rheumatol.2011, 38, 846–854.
139. Cohen, S.B. Cheng, T.T. Chindalore, V. Damjanov, N. Burgos-Vargas, R. Delora, P. Zimany, K. Travers, H. Caulfield, J.P. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum.2009, 60, 335–344.
140. Damjanov, N. Kauffman, R.S. Spencer-Green, G.T. Efficacy, pharmacodynamics, and safety of vx-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009, 60, 1232–1241.
141. Stevens, D.L. Gibbons, A.E. Bergstrom, R. Winn, V. The eagle effect revisited: Efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J. Infect. Dis. 1988, 158, 23–28.